Asunto(s)
Basófilos , Dermatitis Atópica , Queratinocitos , Prurigo , Humanos , Dermatitis Atópica/inmunología , Dermatitis Atópica/complicaciones , Dermatitis Atópica/patología , Dermatitis Atópica/diagnóstico , Prurigo/patología , Prurigo/diagnóstico , Prurigo/inmunología , Prurigo/etiología , Queratinocitos/metabolismo , Queratinocitos/patología , Basófilos/metabolismo , Basófilos/inmunología , Basófilos/patología , Fosforilación , Subunidad alfa del Receptor de Interleucina-4/metabolismo , Subunidad alfa del Receptor de Interleucina-4/inmunología , Masculino , Epidermis/patología , Epidermis/metabolismo , Epidermis/inmunología , Femenino , Janus Quinasa 1RESUMEN
is missing (Short communication).
Asunto(s)
Poroqueratosis , Humanos , Poroqueratosis/diagnóstico , Basófilos , Interleucinas , PruritoAsunto(s)
Anemia Aplásica , Fusarium , Hialohifomicosis , Humanos , Anemia Aplásica/complicaciones , Anemia Aplásica/diagnóstico , PielRESUMEN
Psoriasis is a chronic disease centered on tumor necrosis factor (TNF), interleukin (IL)-23, and IL-17 axis. While psoriasis patients benefit from biologics targeting TNF, IL-17s, and IL-23 nowadays, suppression of these molecules could modulate the balances of immune systems. However, the incidence of autoimmune disease and T-helper 2 reaction during biologic treatments for psoriasis patients is not well documented. We retrospectively examined antinuclear antibody (ANA), eosinophil counts, and immunoglobulin E (IgE) levels for psoriasis patients who underwent biologic treatments in our dermatology clinic from June 10, 2010 to January 29, 2020. A cumulative total of 199 biologic treatments were performed for a total of 128 psoriasis patients. Compared to the non-biologic group of 109 psoriasis patients who received non-biologic treatment, patients treated with infliximab showed more incidents of high ANA (14%, p = 0.039) and high eosinophils (14%, p = 0.021). The use of brodalumab increased incidents of high eosinophils (21%, p = 0.005) but did not affect increase in ANA and IgE. The increase in high IgE level was observed significantly more during the use of risankizumab (15%, p = 0.011). Methotrexate was the most frequently used concomitant systemic treatment, but methotrexate did not affect ANA, eosinophil counts, and IgE levels. Since the biologics for psoriasis treatment modulate the balance of T-helper cells, careful observation is required to detect unexpected changes of systemic immune conditions under biologic treatments.